Structure-based design and characterization of Parkin-activating mutations
Life Science Alliance · 2023
DOI: 10.26508/lsa.202201419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2023. Verfasst von Michael U Stevens und 10 weiteren Autor:innen. Beteiligte Einrichtung: MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NINDS NIH HHS, Michael J Fox Foundation for Parkinson’s Research.
Abstract (Originalsprache)
Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.
- Department of Pharmacology & Therapeutics, McGill University, Montréal, Canada.
- Centre de Recherche en Biologie Structurale, Montpellier, France.
- McGill Parkinson Program, Montreal Neurological Institute, McGill University, Montreal, Canada.
- Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
- Neuroscience PhD Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
ORCID-Profile: Rachel Toth, Wolfdieter Springer, Edward A Fon, Miratul Mk Muqit, Jean-François Trempe
Förderung
- Wellcome Trust
- NINDS NIH HHS
- Michael J Fox Foundation for Parkinson’s Research
- Canada Research Chairs
Zitieren
APA
Stevens, M. U., Croteau, N., Eldeeb, M. A., Antico, O., Zeng, Z. W., Toth, R., Durcan, T. M., Springer, W., Fon, E. A., Muqit, M. M., & Trempe, J. F. (2023). Structure-based design and characterization of Parkin-activating mutations. Life Science Alliance. https://doi.org/10.26508/lsa.202201419
Vancouver
Stevens MU, Croteau N, Eldeeb MA, Antico O, Zeng ZW, Toth R, et al. Structure-based design and characterization of Parkin-activating mutations. Life Science Alliance. 2023. doi:10.26508/lsa.202201419
BibTeX
@article{Stevens2023,
author = {Stevens, Michael U and Croteau, Nathalie and Eldeeb, Mohamed A and Antico, Odetta and Zeng, Zhi Wei and Toth, Rachel and Durcan, Thomas M and Springer, Wolfdieter and Fon, Edward A and Muqit, Miratul Mk and Trempe, Jean-François},
title = {Structure-based design and characterization of Parkin-activating mutations},
journal = {Life Science Alliance},
year = {2023},
doi = {10.26508/lsa.202201419}
}
EUVIMED